CDC Approves Expanded Vaccine Recommendations for Older and Immunocompromised Individuals

The CDC's Advisory Committee on Immunization Practices has updated guidelines to enhance protection against COVID-19, pneumococcal pneumonia, and RSV.

The CDC now recommends a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, with a possible third dose based on clinical decision-making.
The recommended age for the pneumococcal vaccine has been lowered from 65 to 50, expanding eligibility to those at higher risk due to chronic conditions.
A new resolution proposes high-dose influenza vaccines for 18-year-old solid organ transplant recipients on immunosuppressive medications.
The RSV vaccine remains recommended for adults 60 and older at increased risk, with studies showing 80% effectiveness against hospitalizations.
Preliminary evidence suggests clesrovimab could be effective in preventing RSV hospitalizations in infants, pending further review and FDA licensure.